Sun Y, Ramires F J, Zhou G, Ganjam V K, Weber K T
Department of Internal Medicine, University of Missouri Health Sciences Center, Columbia, Missouri 65212, USA.
J Mol Cell Cardiol. 1997 Aug;29(8):2001-12. doi: 10.1006/jmcc.1997.0451.
Myofibroblasts (myoFb) are cells responsible for fibrous tissue formation in injured systemic organs such as the heart. Cultured myoFb, obtained from rat cardiac scar tissue, express genes that encode components requisite for angiotensin (Ang) II generation, which in turn regulates myoFb collagen turnover in an autocrine/paracrine manner. In this study, we tested the hypothesis that these wound-healing fibroblast-like cells and locally generated Ang II are involved in other repairing tissue. To test this hypothesis, we used a granuloma pouch model, where a subcutaneous air sac is created followed by injection of croton oil. Pouch tissue was collected at days 4, 7, 14 and 21. The presence of myoFb was determined by immunohistochemical alpha-smooth muscle actin (alpha-SMA) labeling and collagen accumulation by picrosirius red staining. Angiotensin converting enzyme (ACE) and Ang II receptor binding were detected by in vitro quantitative autoradiography using 125I-351A and 125I[Sar1, Ile8]Ang II, respectively, while Ang II receptor subtype was defined by displacement studies using either an AT1 (losartan) or AT2 (PD123177) receptor antagonist. Cells expressing ACE were determined by immunohistochemistry. Ang II content in pouch tissue was measured by radioimmunoassay following HPLC separation while its capacity to generate Ang II was assessed in tissue bath, with and without exogenous Ang I or lisinopril, an ACE inhibitor. Collagen accumulation in pouch tissue was examined by determining hydroxyproline content in response to lisinopril, AT1 or AT2 receptor antagonists (losartan or PD123177). In pouch tissue, we found: (1) myoFb at day 4 which became more extensive at days 7, 14 and 21; (2) morphologic evidence of collagen deposition evident at day 4, which gradually became more extensive thereafter; (3) ACE and Ang II receptor binding was evident at day 4 and remained invariant on days 7, 14 and 21; (4) the predominant Ang II receptor subtype expressed was AT1; (5) myoFb express ACE and AT1 receptors; (6) picogram quantities of Ang II (per g tissue) was evident on days 7, 14 and 21; and (7) Ang II was generated from Ang I substrate. Lisinopril and losartan, but not PD123177, significantly attenuated pouch weight and accumulation of collagen. Thus, in this model of cutaneous repair, the appearance of myoFb is associated with Ang II generation that regulates fibrogenesis by AT1 receptor binding. Signals involved in the appearance of myoFb remain uncertain. Further studies are required to address the regulation of Ang II generation in pouch tissue of the rat.
肌成纤维细胞(myoFb)是在诸如心脏等受损全身器官中负责纤维组织形成的细胞。从大鼠心脏瘢痕组织中获取的培养肌成纤维细胞表达编码血管紧张素(Ang)II生成所需成分的基因,而Ang II又以自分泌/旁分泌方式调节肌成纤维细胞的胶原蛋白周转。在本研究中,我们检验了这样一个假设,即这些伤口愈合的成纤维细胞样细胞和局部产生的Ang II参与其他组织修复。为验证这一假设,我们使用了肉芽肿袋模型,即先创建一个皮下气囊,然后注射巴豆油。在第4、7、14和21天收集袋组织。通过免疫组织化学α-平滑肌肌动蛋白(α-SMA)标记确定肌成纤维细胞的存在,并用天狼星红染色检测胶原蛋白积累。分别使用125I-351A和125I[Sar1,Ile8]Ang II通过体外定量放射自显影检测血管紧张素转换酶(ACE)和Ang II受体结合,而使用AT1(氯沙坦)或AT2(PD123177)受体拮抗剂的置换研究来确定Ang II受体亚型。通过免疫组织化学确定表达ACE的细胞。袋组织中的Ang II含量在HPLC分离后通过放射免疫测定法测量,而其产生Ang II的能力在组织浴中评估,分别添加和不添加外源性Ang I或ACE抑制剂赖诺普利。通过测定对赖诺普利、AT1或AT2受体拮抗剂(氯沙坦或PD123177)反应后的羟脯氨酸含量来检查袋组织中的胶原蛋白积累。在袋组织中,我们发现:(1)第4天出现肌成纤维细胞,在第7、14和21天变得更加广泛;(2)第4天有胶原蛋白沉积的形态学证据,此后逐渐变得更加广泛;(3)第4天ACE和Ang II受体结合明显,在第7、14和21天保持不变;(4)表达的主要Ang II受体亚型是AT1;(5)肌成纤维细胞表达ACE和AT1受体;(6)第7、14和21天每克组织中有皮克量的Ang II明显存在;(7)Ang II由Ang I底物产生。赖诺普利和氯沙坦,但不是PD123177,显著减轻袋重量和胶原蛋白积累。因此,在这个皮肤修复模型中,肌成纤维细胞的出现与Ang II生成相关,Ang II通过AT1受体结合调节纤维生成。肌成纤维细胞出现所涉及的信号仍不确定。需要进一步研究来探讨大鼠袋组织中Ang II生成的调节。
J Mol Cell Cardiol. 1997-8
J Mol Cell Cardiol. 1998-7
J Mol Cell Cardiol. 1997-5
J Mol Cell Cardiol. 1999-5
Cardiovasc Res. 1994-11
Cardiovasc Res. 1996-4
J Pharmacol Exp Ther. 2001-7
Biomolecules. 2024-10-27
J Cardiovasc Dev Dis. 2019-9-23
Plast Reconstr Surg Glob Open. 2017-7-24
Expert Rev Cardiovasc Ther. 2016
G Ital Nefrol. 2014
Nat Rev Cardiol. 2012-12-4
Am J Physiol Heart Circ Physiol. 2012-3-23